Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Income from Continuing Operations (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Income from Continuing Operations for 11 consecutive years, with 92234000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 26.69% to 92234000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 411795000.0 through Dec 2025, up 15.35% year-over-year, with the annual reading at 411795000.0 for FY2025, 15.35% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 92234000.0 at Intellia Therapeutics, up from 104763000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 46205000.0 in Q1 2021, with the low at 143706000.0 in Q1 2022.
  • Average Income from Continuing Operations over 5 years is 103994950.0, with a median of 104159000.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations crashed 211.02% in 2022, then soared 30.43% in 2023.
  • Over 5 years, Income from Continuing Operations stood at 79912000.0 in 2021, then crashed by 31.06% to 104733000.0 in 2022, then decreased by 21.67% to 127433000.0 in 2023, then increased by 1.27% to 125816000.0 in 2024, then rose by 26.69% to 92234000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 92234000.0, 104763000.0, and 102594000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.